The decline in EPS has likely disappointed the market, makin...
The decline in EPS has likely disappointed the market, making investors hesitant to buy. Despite the recent share price increase, the long-term performance has been less impressive, significantly under-performing the market.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment